Jazz Pharmaceuticals (JAZZ) Projected to Announce Quarterly Earnings on Monday

Jazz Pharmaceuticals (NASDAQ:JAZZ) is expected to issue its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Jazz Pharmaceuticals to announce earnings of $6.26 per share and revenue of $1.21 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($8.25) earnings per share. On average, analysts expect Jazz Pharmaceuticals to post $18.24 EPS for the current fiscal year and $21.91 EPS for the next fiscal year.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $214.00 on Monday. The firm’s 50 day moving average price is $236.11 and its 200-day moving average price is $233.16. The company has a market cap of $13.89 billion, a PE ratio of 14.76, a P/E/G ratio of 0.26 and a beta of 0.37. Jazz Pharmaceuticals has a 52-week low of $128.80 and a 52-week high of $266.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78.

Wall Street Analyst Weigh In

JAZZ has been the subject of several analyst reports. Canaccord Genuity Group set a $300.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 26th. Barclays boosted their price objective on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the stock an “overweight” rating in a report on Thursday, September 10th. Truist Financial upped their price objective on Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a research report on Wednesday, October 7th. TD Cowen increased their target price on Jazz Pharmaceuticals from $275.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, August 4th. Finally, Piper Sandler lifted their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $290.85.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Renee D. Gala sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $243.03, for a total value of $486,060.00. Following the completion of the sale, the chief executive officer owned 143,394 shares of the company’s stock, valued at $34,849,043.82. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the sale, the executive vice president owned 47,671 shares of the company’s stock, valued at approximately $11,485,850.74. This trade represents a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 100,121 shares of company stock valued at $24,855,802 over the last 90 days. 4.10% of the stock is owned by corporate insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.